Kooperativer Bibliotheksverbund

UID:

Format: 1 online resource (459 p.)

Edition: 1st ed.

ISBN: 9786611279608 , 0-08-057032-1

Content: Antitumor chemotherapy is nowadays a very active field of research, and a huge amount of information on the topic is generated every year. Although many books are available that deal with clinical aspects of cancer chemotherapy, this book addresses the need for an updated treatment from the point of view of medicinal chemistry and drug design. The focus of Medicinal Chemistry of Anticancer Drugs is on the mechanism of action of antitumor drugs from the molecular point of view and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents,

Note: Description based upon print version of record. , Front Cover; Medicinal Chemistry of Anticancer Drugs; Copyright Page; Preface; Abbreviations; Chapter 1: Introduction; 2. A Brief Account of the Role of Chemistry in Cancer Chemotherapy; 3. Natural Products in Cancer Chemotherapy; 4. A Brief Comment About Cancer Nanotechnology; References; Chapter 2: Antimetabolites; 5. Inhibitors of Dihydrofolate Reductase (DHFR); 9. Antimetabolite Enzymes; Chapter 3: Anticancer Drugs That Inhibit Hormone Action; 1. Introduction; 9. Compounds Acting on Other Proteins of the Nuclear Receptor Superfamily: Retinoids , Chapter 4: Anticancer Drugs Acting via Radical Species, Photosensitizers and Photodynamic Therapy of Cancer4. Mitoxantrone and Related Quinones; 8. Enediyne Antibiotics; Chapter 5: DNA Alkylating Agents; 3. Aziridines (Ethyleneimines); Chapter 6: Alkylating and Non-Alkylating Compounds Interacting with the DNA Minor Groove; Chapter 7: DNA Intercalators and Topoisomerase Inhibitors; 1. DNA Intercalation and Its Consequences; Chapter 8: Anticancer Drugs Targeting Tubulin and Microtubules; 2. Drugs That Inhibit Microtubule Polymerization at High Concentrations , Chapter 9: Drugs That Inhibit Signalling Pathways for Tumor Cell Growth and Proliferation1. Introduction: The Role of Protein Kinases in Cancer; 4. Inhibitors of Serine-Threonine Kinases; 6. Inhibitors of Farnesyldiphosphate Synthase and Geranylgeranyldiphosphate Synthase; Chapter 10: Other Approaches to Targeted Therapy; Chapter 11: Drug Targeting in Anticancer Chemotherapy; 4. Macromolecular Small-Drug Carrier Systems; 5. Polymer-Directed Enzyme Prodrug Therapy (PDEPT); 6. Folate Receptor-Targeted Chemotherapy and Immunotherapy of Cancer , Chapter 12: Drugs That Modulate Resistance to Antitumor Agents1. ATP-Binding Cassette Efflux Pumps in Anticancer Drug Resistance; References; Chapter 13: Cancer Chemoprevention; 1. Introduction; 2. Ligands for Nuclear Receptors in Cancer Chemoprevention; 3. Anti-Inflammatory Agents and Antioxidants in Cancer Chemoprevention; Index , English

Additional Edition: ISBN 0-444-52824-5

Language: English

UID:

Format: 1 Schellack-Schallpl , 78 UpM , 25 cm

Note: Enth.: Arrancame el corazon / Leoncio Aguero. Embrujo antillano / J. Carbo Ménendez

Language: Undetermined

UID:

Format: 6 ungez. Bl

Language: Spanish

UID:

Note: In: Estudios internacionales. - Santiago de Chile , Año 23(1990), Nr. 92, S. 444-463

In: year:1990

Language: Spanish

UID:

Note: In: Revista paraguaya de sociología. - Asunción , Año 24(1987), Nr. 68, S. 37-63

In: year:1987

Language: Spanish

UID:

Note: In: Caravelle. - Toulouse , 50(1988), S. 35-48

In: year:1988

Language: Spanish

UID:

Note: In: Pastos y forrajes. - Matanzas , T. 5(1982), Nr. 3, S. 251-263, mit Kt. u. Tab

In: year:1982

Language: Spanish

UID:

Format: 1 online resource (767 p.)

Edition: 2nd ed.

ISBN: 0-444-62667-0

Content: Medicinal Chemistry of Anticancer Drugs, Second Edition, provides an updated treatment from the point of view of medicinal chemistry and drug design, focusing on the mechanism of action of antitumor drugs from the molecular level, and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents. Antitumor chemotherapy is a very active field of research, and a huge amount of information on the topic is generated every year. Cytotoxic chemotherapy is gradually being supplemented by a new generation of drugs that recognize specific targets on the

Note: Description based upon print version of record. , Front Cover; Medicinal Chemistry of Anticancer Drugs; Copyright; Contents; Foreword; Preface; Abbreviations; Chapter 1: General Aspects of Cancer Chemotherapy; 1. Introduction: Some General Comments About Cancer; 2. Tumorigenesis and Oncogenes: Pharmacogenomics; 3. Early Diagnosis of Cancer and Its Therapeutic Relevance; 4. A Brief History of Cancer Chemotherapy; 5. General Comments About Anticancer Drug Discovery; 6. Combination Therapy and Personalized Anticancer Treatments; 7. Natural Products in Cancer Chemotherapy; 8. A Brief Comment About Cancer Nanotechnology , 9. Summary of FDA-Approved Anticancer DrugsReferences; Chapter 2: Antimetabolites That Interfere with Nucleic Acid Biosynthesis; 1. Introduction; 2. Inhibitors of the Biosynthesis of Uridylic Acid; 3. Inhibitors of Ribonucleotide Reductase; 3.1. Structure and Catalytic Cycle of Ribonucleotide Reductase; 3.2. Gallium Salts and Complexes; 3.3. Radical Scavengers; 3.4. Substrate Analogs as Ribonucleotide Reductase Inhibitors; 3.5. Allosteric Inhibition of Ribonucleotide Reductase via Inhibition of Purine Nucleoside Phosphorylase; 4. Inhibitors of the Biosynthesis of Thymidilic Acid , 4.1. Thymidylate Synthase4.2. 5-Fluorouracil and Floxuridine; 4.3. 5-Fluorouracil Prodrugs; 4.4. Modulation of 5-Fluorouracil Activity; 4.4.1. Decreased Degradation of 5-FU; 4.4.2. Enhancement of the Inhibition of Thymidylate Synthase by 5-FU; 4.4.3. Enhancement of 5-FU Activation; 4.5. Trifluridine; 4.6. Folate-Based Thymidylate Synthase Inhibitors; 5. Inhibitors of Dihydrofolate Reductase; 5.1. Classical DHFR Inhibitors; 5.2. Nonclassical (Lipophilic) DHFR Inhibitors; 6. Inhibitors of the De Novo Purine Biosynthesis Pathway; 6.1. Inhibitors of PRPP Amidotransferase , 6.2. Inhibitors of Glycinamide Ribonucleotide Formyltransferase6.3. Inhibitors of Phosphoribosylformylglycinamidine Synthetase; 6.4. Inhibitors of 5-Aminoimidazole-4-Carboxamide Ribonucleotide Formyltransferase; 6.5. Thiopurines and Related Compounds; 7. Inhibitors of Adenosine Deaminase; 8. Inhibitors of Late Stages in DNA Synthesis; 8.1. Pyrimidine Nucleosides; 8.2. Purine Nucleosides; 9. Antimetabolite Enzymes; References; Chapter 3: Anticancer Drugs That Modulate Hormone Action; 1. Introduction; 2. Estrogens and Their Involvement in Carcinogenesis; 3. Antiestrogens as Antitumor Drugs , 3.1. Nonsteroidal Antiestrogens (Selective Estrogen Receptor Modulators)3.2. Steroidal Antiestrogens; 4. Aromatase Inhibitors; 4.1. Aromatase Mechanism of Action; 4.2. Steroidal Aromatase Inhibitors (Type I Inhibitors); 4.3. C-19 Modified Substrate Analogs; 4.4. 4-Hydroxyandrostenedione Derivatives; 4.5. Steroids with Additional Unsaturations at the A and B Rings; 4.6. Structure-Activity Relationships in Steroidal Aromatase Inhibitors; 4.7. Nonsteroidal Aromatase Inhibitors (Type II); 5. Steroid Sulfatase Inhibitors; 6. Androgen-Related Antitumor Agents; 6.1. Antiandrogens , 6.1.1. Steroidal Antiandrogens , English

Additional Edition: ISBN 0-444-62649-2

Language: English

UID:

Format: 1 online resource (767 p.)

Edition: 2nd ed.

ISBN: 0-444-62667-0

Content: Medicinal Chemistry of Anticancer Drugs, Second Edition, provides an updated treatment from the point of view of medicinal chemistry and drug design, focusing on the mechanism of action of antitumor drugs from the molecular level, and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents. Antitumor chemotherapy is a very active field of research, and a huge amount of information on the topic is generated every year. Cytotoxic chemotherapy is gradually being supplemented by a new generation of drugs that recognize specific targets on the

Note: Description based upon print version of record. , Front Cover; Medicinal Chemistry of Anticancer Drugs; Copyright; Contents; Foreword; Preface; Abbreviations; Chapter 1: General Aspects of Cancer Chemotherapy; 1. Introduction: Some General Comments About Cancer; 2. Tumorigenesis and Oncogenes: Pharmacogenomics; 3. Early Diagnosis of Cancer and Its Therapeutic Relevance; 4. A Brief History of Cancer Chemotherapy; 5. General Comments About Anticancer Drug Discovery; 6. Combination Therapy and Personalized Anticancer Treatments; 7. Natural Products in Cancer Chemotherapy; 8. A Brief Comment About Cancer Nanotechnology , 9. Summary of FDA-Approved Anticancer DrugsReferences; Chapter 2: Antimetabolites That Interfere with Nucleic Acid Biosynthesis; 1. Introduction; 2. Inhibitors of the Biosynthesis of Uridylic Acid; 3. Inhibitors of Ribonucleotide Reductase; 3.1. Structure and Catalytic Cycle of Ribonucleotide Reductase; 3.2. Gallium Salts and Complexes; 3.3. Radical Scavengers; 3.4. Substrate Analogs as Ribonucleotide Reductase Inhibitors; 3.5. Allosteric Inhibition of Ribonucleotide Reductase via Inhibition of Purine Nucleoside Phosphorylase; 4. Inhibitors of the Biosynthesis of Thymidilic Acid , 4.1. Thymidylate Synthase4.2. 5-Fluorouracil and Floxuridine; 4.3. 5-Fluorouracil Prodrugs; 4.4. Modulation of 5-Fluorouracil Activity; 4.4.1. Decreased Degradation of 5-FU; 4.4.2. Enhancement of the Inhibition of Thymidylate Synthase by 5-FU; 4.4.3. Enhancement of 5-FU Activation; 4.5. Trifluridine; 4.6. Folate-Based Thymidylate Synthase Inhibitors; 5. Inhibitors of Dihydrofolate Reductase; 5.1. Classical DHFR Inhibitors; 5.2. Nonclassical (Lipophilic) DHFR Inhibitors; 6. Inhibitors of the De Novo Purine Biosynthesis Pathway; 6.1. Inhibitors of PRPP Amidotransferase , 6.2. Inhibitors of Glycinamide Ribonucleotide Formyltransferase6.3. Inhibitors of Phosphoribosylformylglycinamidine Synthetase; 6.4. Inhibitors of 5-Aminoimidazole-4-Carboxamide Ribonucleotide Formyltransferase; 6.5. Thiopurines and Related Compounds; 7. Inhibitors of Adenosine Deaminase; 8. Inhibitors of Late Stages in DNA Synthesis; 8.1. Pyrimidine Nucleosides; 8.2. Purine Nucleosides; 9. Antimetabolite Enzymes; References; Chapter 3: Anticancer Drugs That Modulate Hormone Action; 1. Introduction; 2. Estrogens and Their Involvement in Carcinogenesis; 3. Antiestrogens as Antitumor Drugs , 3.1. Nonsteroidal Antiestrogens (Selective Estrogen Receptor Modulators)3.2. Steroidal Antiestrogens; 4. Aromatase Inhibitors; 4.1. Aromatase Mechanism of Action; 4.2. Steroidal Aromatase Inhibitors (Type I Inhibitors); 4.3. C-19 Modified Substrate Analogs; 4.4. 4-Hydroxyandrostenedione Derivatives; 4.5. Steroids with Additional Unsaturations at the A and B Rings; 4.6. Structure-Activity Relationships in Steroidal Aromatase Inhibitors; 4.7. Nonsteroidal Aromatase Inhibitors (Type II); 5. Steroid Sulfatase Inhibitors; 6. Androgen-Related Antitumor Agents; 6.1. Antiandrogens , 6.1.1. Steroidal Antiandrogens , English

Additional Edition: ISBN 0-444-62649-2

Language: English

UID:

Format: 1 online resource (767 p.)

Edition: 2nd ed.

ISBN: 0-444-62667-0

Content: Medicinal Chemistry of Anticancer Drugs, Second Edition, provides an updated treatment from the point of view of medicinal chemistry and drug design, focusing on the mechanism of action of antitumor drugs from the molecular level, and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents. Antitumor chemotherapy is a very active field of research, and a huge amount of information on the topic is generated every year. Cytotoxic chemotherapy is gradually being supplemented by a new generation of drugs that recognize specific targets on the

Note: Description based upon print version of record. , Front Cover; Medicinal Chemistry of Anticancer Drugs; Copyright; Contents; Foreword; Preface; Abbreviations; Chapter 1: General Aspects of Cancer Chemotherapy; 1. Introduction: Some General Comments About Cancer; 2. Tumorigenesis and Oncogenes: Pharmacogenomics; 3. Early Diagnosis of Cancer and Its Therapeutic Relevance; 4. A Brief History of Cancer Chemotherapy; 5. General Comments About Anticancer Drug Discovery; 6. Combination Therapy and Personalized Anticancer Treatments; 7. Natural Products in Cancer Chemotherapy; 8. A Brief Comment About Cancer Nanotechnology , 9. Summary of FDA-Approved Anticancer DrugsReferences; Chapter 2: Antimetabolites That Interfere with Nucleic Acid Biosynthesis; 1. Introduction; 2. Inhibitors of the Biosynthesis of Uridylic Acid; 3. Inhibitors of Ribonucleotide Reductase; 3.1. Structure and Catalytic Cycle of Ribonucleotide Reductase; 3.2. Gallium Salts and Complexes; 3.3. Radical Scavengers; 3.4. Substrate Analogs as Ribonucleotide Reductase Inhibitors; 3.5. Allosteric Inhibition of Ribonucleotide Reductase via Inhibition of Purine Nucleoside Phosphorylase; 4. Inhibitors of the Biosynthesis of Thymidilic Acid , 4.1. Thymidylate Synthase4.2. 5-Fluorouracil and Floxuridine; 4.3. 5-Fluorouracil Prodrugs; 4.4. Modulation of 5-Fluorouracil Activity; 4.4.1. Decreased Degradation of 5-FU; 4.4.2. Enhancement of the Inhibition of Thymidylate Synthase by 5-FU; 4.4.3. Enhancement of 5-FU Activation; 4.5. Trifluridine; 4.6. Folate-Based Thymidylate Synthase Inhibitors; 5. Inhibitors of Dihydrofolate Reductase; 5.1. Classical DHFR Inhibitors; 5.2. Nonclassical (Lipophilic) DHFR Inhibitors; 6. Inhibitors of the De Novo Purine Biosynthesis Pathway; 6.1. Inhibitors of PRPP Amidotransferase , 6.2. Inhibitors of Glycinamide Ribonucleotide Formyltransferase6.3. Inhibitors of Phosphoribosylformylglycinamidine Synthetase; 6.4. Inhibitors of 5-Aminoimidazole-4-Carboxamide Ribonucleotide Formyltransferase; 6.5. Thiopurines and Related Compounds; 7. Inhibitors of Adenosine Deaminase; 8. Inhibitors of Late Stages in DNA Synthesis; 8.1. Pyrimidine Nucleosides; 8.2. Purine Nucleosides; 9. Antimetabolite Enzymes; References; Chapter 3: Anticancer Drugs That Modulate Hormone Action; 1. Introduction; 2. Estrogens and Their Involvement in Carcinogenesis; 3. Antiestrogens as Antitumor Drugs , 3.1. Nonsteroidal Antiestrogens (Selective Estrogen Receptor Modulators)3.2. Steroidal Antiestrogens; 4. Aromatase Inhibitors; 4.1. Aromatase Mechanism of Action; 4.2. Steroidal Aromatase Inhibitors (Type I Inhibitors); 4.3. C-19 Modified Substrate Analogs; 4.4. 4-Hydroxyandrostenedione Derivatives; 4.5. Steroids with Additional Unsaturations at the A and B Rings; 4.6. Structure-Activity Relationships in Steroidal Aromatase Inhibitors; 4.7. Nonsteroidal Aromatase Inhibitors (Type II); 5. Steroid Sulfatase Inhibitors; 6. Androgen-Related Antitumor Agents; 6.1. Antiandrogens , 6.1.1. Steroidal Antiandrogens , English

Additional Edition: ISBN 0-444-62649-2

Language: English